

1 **Intrahepatic transcriptomics differentiate advanced fibrosis and clinical outcomes**  
2 **in adults with the Fontan circulation**

3 Katia Bravo-Jaimes, MD<sup>1, 2</sup>; Xiuju Wu, MD, PhD<sup>3</sup>; Leigh C Reardon, MD<sup>2, 4</sup>; Gentian  
4 Lluri, MD, PhD<sup>2, 3</sup>; Jeannette P Lin, MD<sup>2, 3</sup>; Jeremy P Moore, MD, MS<sup>2, 4</sup>; Glen Van  
5 Arsdell, MD<sup>2, 3</sup>; Reshma Biniwale, MD; Ming-Sing Si, MD, PhD; Bitu V Naini, MD<sup>5</sup>;  
6 Robert Venick, MD<sup>6</sup>; Sammy Saab, MD, MPH<sup>6</sup>; Christopher L Wray, MD<sup>7</sup>; Reid Ponder<sup>2</sup>;  
7 Carl Rosenthal<sup>8</sup>; Alexandra Klomhaus, MS, PhD<sup>9</sup>; Kristina I Böstrom, MD, PhD<sup>3</sup>; Jamil A  
8 Aboulhosn, MD<sup>2,3</sup>; Fady M Kaldas, MD<sup>8</sup>

9 <sup>1</sup> Department of Cardiovascular Diseases. Mayo Clinic Jacksonville Florida

10 <sup>2</sup> Ahmanson/UCLA Adult Congenital Heart Disease Center. University of California, Los  
11 Angeles

12 <sup>3</sup> Division of Cardiology. Department of Medicine. University of California, Los Angeles

13 <sup>4</sup> Department of Pediatric Cardiology. University of California, Los Angeles Mattel  
14 Children's Hospital

15 <sup>5</sup> Department of Pathology and Lab Services. University of California, Los Angeles

16 <sup>6</sup> Department of Gastroenterology, Hepatology and Nutrition. University of California,  
17 Los Angeles Mattel Children's Hospital

18 <sup>7</sup> Department of Anesthesiology. University of California, Los Angeles.

19 <sup>8</sup> Dumont-UCLA Liver Transplant Center. Department of Surgery. University of  
20 California, Los Angeles

21 <sup>9</sup> Department of Medicine Statistics Core. David Geffen School of Medicine. University  
22 of California, Los Angeles

23 **Word count: 2378**

24 **Sources of funding:** Adult Congenital Heart Association Research Grant 2021 (K.B.J.),  
25 NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant  
26 Number UL1TR001881 (A.K.), NIH/NHLBI Grant Number HL81397 (K.I.B.), NIH/NHLBI  
27 Grant Number HL154548 (K.I.B.). Streisand/American Heart Association Endowed  
28 Chair in Cardiology (J.A.H.). Kelly Lee Tarantello Endowed Chair in Integrative Liver  
29 Transplantation (F.M.K.).

30

31 **Disclosures:** The authors declare no conflicts of interest.

32

33 **Corresponding author:**

34 Fady M Kaldas, MD

35 Dumont-UCLA Liver Transplant Center. Department of Surgery. David Geffen School of  
36 Medicine at UCLA

37 757 Westwood Plaza, Suite 8501, Los Angeles, CA 90095, USA.

38 Email: [FKaldas@mednet.ucla.edu](mailto:FKaldas@mednet.ucla.edu)

## 39 **ABSTRACT**

### 40 **Background**

41 The molecular mechanisms underlying Fontan associated liver disease (FALD) remain  
42 largely unknown. We aimed to assess intrahepatic transcriptomic differences among  
43 patients with FALD according to the degree of liver fibrosis and clinical outcomes.

### 44 **Methods**

45 This retrospective cohort study included adults with the Fontan circulation at the  
46 Ahmanson/UCLA Adult Congenital Heart Disease Center. Clinical, laboratory, imaging  
47 and hemodynamic data prior to the liver biopsy were extracted from medical records.  
48 Patients were classified into early (F1-F2) or advanced fibrosis (F3-F4). RNA was  
49 isolated from formalin-fixed paraffin embedded liver biopsy samples; RNA libraries were  
50 constructed using rRNA depletion method and sequencing was performed on Illumina  
51 Novaseq 6000. Differential gene expression and gene ontology analyses were carried  
52 out using DESeq2 and Metascape. Medical records were comprehensively reviewed for  
53 a composite clinical outcome which included decompensated cirrhosis, hepatocellular  
54 carcinoma, liver transplantation, protein-losing enteropathy, chronic kidney disease  
55 stage 4 or higher, or death.

### 56 **Results**

57 Patients with advanced fibrosis had higher serum BNP levels and Fontan, mean  
58 pulmonary artery and capillary wedge pressures. The composite clinical outcome was  
59 present in 23 patients (22%) and was predicted by age at Fontan, right ventricular  
60 morphology and presence of aortopulmonary collaterals on multivariable analysis.  
61 Samples with advanced fibrosis had 228 up-regulated genes compared to early fibrosis.

62 Samples with the composite clinical outcome had 894 up-regulated genes compared to  
63 those without it. A total of 136 up-regulated genes were identified in both comparisons  
64 and these genes were enriched in cellular response to cytokine stimulus, response to  
65 oxidative stress, VEGFA-VEGFR2 signaling pathway, TGF-beta signaling pathway, and  
66 vasculature development.

## 67 **Conclusions**

68 Patients with FALD and advanced liver fibrosis or the composite clinical outcome exhibit  
69 up-regulated genes including pathways related to inflammation, congestion, and  
70 angiogenesis. This adds further insight into FALD pathophysiology.

71 **KEYWORDS:** single ventricle, liver fibrosis, transcriptomics, Fontan-associated liver  
72 disease, Fontan outcomes

73 Patients with a functional single ventricle represent a population with highly complex  
74 anatomy, physiology, and management challenges. Since its first description in 1971,  
75 the Fontan operation has been performed for palliation of single ventricle physiology<sup>1</sup>.  
76 Several evolutionary modifications have been made to improve long-term outcomes, but  
77 short-and long-term complications including Fontan-associated liver disease (FALD)<sup>2</sup>,  
78 continue to occur after Fontan palliation. Preliminary studies have demonstrated that  
79 hepatic fibrosis develops early after the Fontan palliation<sup>3</sup> and will be present in virtually  
80 all patients<sup>2-4</sup>, depending mostly on duration of Fontan physiology rather than  
81 hemodynamics<sup>4,5</sup>. Decompensated cirrhosis will only be apparent in some patients and  
82 a minority will develop hepatocellular carcinoma<sup>5</sup>. The pathophysiology of FALD  
83 includes chronic passive congestion due to elevated systemic venous pressures<sup>6,7</sup>, as  
84 well as chronic low cardiac output. This physiology results in decreased oxygen delivery  
85 to centrilobular cells, zone 3 hepatocytes atrophy, sinusoidal fibrosis, eventual bridging  
86 fibrosis and finally cardiac cirrhosis<sup>8,9</sup>.

87 With >70,000 post-Fontan patients worldwide now reaching adulthood<sup>2</sup>, there is a need  
88 to better characterize the molecular pathways underlying FALD. We assessed  
89 intrahepatic gene expression profiles in adults with the Fontan circulation in comparison  
90 with donor controls to test the hypotheses that (1) despite clinical heterogeneity,  
91 patients with the Fontan circulation and advanced fibrosis exhibit a distinctive gene  
92 transcriptome that contrasts with that of early fibrosis and controls; (2) these differences  
93 involve enriched pathways related to angiogenesis; and (3) molecular phenotyping can  
94 identify Fontan subgroups that exhibit distinct clinical features and prognosis.

95

## 96 **METHODS**

### 97 **Fontan study population**

98 The Fontan patient group consisted of adults ( $\geq 18$  years old) who have had at least  
99 two visits at the Ahmanson/UCLA Adult Congenital Heart Disease Center between  
100 January 2005 and December 2021 and had tissue available from at least one liver  
101 biopsy. The study was approved by the UCLA Institutional Review Board. Baseline  
102 clinical, laboratory, imaging and hemodynamic information were extracted from medical  
103 records and the results closest to the date of liver biopsy within a 1-year period (6  
104 months before and after the liver biopsy) were recorded. These variables included age,  
105 sex, height, weight, body mass index (BMI), race/ethnicity, cardiac anatomy, genetic  
106 syndromes, age at Fontan, cardiac medications (beta-blockers, antiplatelets,  
107 anticoagulants, loop diuretics, renin-angiotensin-aldosterone system inhibitors,  
108 phosphodiesterase 5 inhibitors, endothelin receptor antagonists, antiarrhythmics),  
109 diabetes, hypertension, obesity (BMI  $>30$ ), hepatitis C, alcohol use, arrhythmias, NYHA  
110 class, single ventricle systolic function and atrioventricular valve regurgitation  
111 (echocardiographic or by cardiac magnetic resonance), creatinine, platelet count,  
112 hemoglobin, AST, ALT, GGT, INR, AFP, total bilirubin, BNP, liver ultrasound, MRI and  
113 CT characteristics, exercise-induced desaturation, peak  $VO_2$ ,  $VE/VCO_2$ , high exercise  
114 capacity ( $>80\%$  age, sex matched peak  $VO_2$ )<sup>10</sup>, low exercise capacity ( $<50\%$  age, sex  
115 matched peak  $VO_2$ )<sup>10</sup>, Fontan pressures, pulmonary artery pressures, pulmonary  
116 capillary wedge pressures, single ventricle end-diastolic pressure,  $Q_s$ , pulmonary  
117 vascular resistance (PVR), PVR index (PVRi), systemic vascular resistance (SVR), SVR  
118 index (SVRi), Fontan pathway obstruction (angiographic evidence of stenosis along the

119 Fontan pathway with at least 1 mmHg gradient)<sup>10</sup>, diastolic dysfunction (single ventricle  
120 end-diastolic pressure or pulmonary capillary wedge pressure  $\geq$  12 mmHg at baseline  
121 or  $\geq$  15 mmHg after volume or contrast load)<sup>10</sup>, elevated PVR (PVRi  $\geq$  2 WU\*m2)<sup>10</sup>,  
122 aortopulmonary and venous-venous collaterals (assessed by angiography).

### 123 **Liver tissue procurement and processing**

124 Archived formalin-fixed paraffin embedded (FFPE) liver tissue from patients with the  
125 Fontan circulation who have had liver biopsies were processed by the Translational  
126 Pathology Core Laboratory. Slides were independently interpreted by two liver  
127 pathologists and METAVIR scores were determined by consensus. Advanced liver  
128 fibrosis was defined as those having METAVIR F3-F4 fibrosis on liver biopsy. Normal  
129 liver tissue and post-liver transplant biopsy tissue were used as controls.

### 130 **RNA preparation and sequencing**

131 Five to six 10  $\mu$ M sections from each FFPE tissue block were used for RNA extraction.  
132 Total RNA was isolated from the liver sections using RNeasy FFPE kit (Qiagen, Cat.  
133 No. 73504). RNA samples with DV200  $\geq$  30% were processed for library construction  
134 using rRNA depletion methods (Roche, KAPA RNA HyperPrep Kit w/ Ribo Erase,  
135 KK8561). Sequencing was performed using Illumina Novaseq 6000 platform (2x100bp)  
136 to the depth of 28-110 million reads per library at UCLA Technology Center for  
137 Genomics & Bioinformatics. The FASTQ raw reads were mapped using Spliced  
138 Transcripts Alignment to a Reference (STAR, version 2.7.10a)<sup>11</sup> to the human reference  
139 genome GRCh38 with default parameters. The counts for each gene were generated  
140 using `-quantMode GeneCounts` function along the STAR alignment.

141

## 142 **Differential gene expression analyses**

143 Transcripts were first quality filtered to exclude the genes with a mean read count < 5 in  
144 each sample. Transcripts without gene annotation were also excluded using R package  
145 biomaRt. Data normalization and differential expression analyses were carried out using  
146 R package DESeq2 (version 1.38.1)<sup>11</sup>. After estimation of size factors and dispersion,  
147 the likelihood ratio test (LRT) with negative binomial generalized linear model (NB GLM)  
148 was used for fitting. Sequencing depth normalized gene counts were obtained from  
149 DESeqDataSet. Differentially expressed genes (DEGs) were defined using the 5% false  
150 discovery rate (Benjamini-Hochberg method) threshold and two-fold change for  
151 significance. To minimize the possible false discoveries, DESeq function were  
152 performed again following permutations on the variables of fibrosis or composite clinical  
153 outcome. The genes identified in the differential test after permutations were filtered out.

## 154 **Gene ontology and gene-disease association analyses**

155 Gene ontology and gene-disease association (DisGeNet) enrichment analyses were  
156 performed using Metascape platform<sup>12</sup>. The DisGeNET platform integrates information  
157 of human gene-disease associations from various repositories<sup>13,14</sup>.

## 158 **Statistical analysis of clinical variables**

159 Continuous and categorical data were reported as median (interquartile range) and  
160 number (percentage), respectively. Between-group differences in the baseline variables  
161 described above were examined using Kruskal-Wallis or Pearson chi-square (or  
162 Fisher's exact) tests as appropriate. Variables found to significantly ( $p < 0.05$ ) differ  
163 between the groups were used in covariate adjusted models. A composite clinical  
164 outcome included decompensated cirrhosis (ascites requiring paracentesis, esophageal



165 variceal bleeding, or hepatic encephalopathy), hepatocellular carcinoma, need for liver  
166 transplantation, protein-losing enteropathy, chronic kidney disease stage 4 or higher, or  
167 death. An unadjusted cumulative incidence function and Gray's Test, stratified by early  
168 vs advanced fibrosis was used to compare time to event relative to the date of Fontan  
169 between the two groups. A multivariable Cox proportional hazards model was built  
170 using covariates that were associated in univariate analysis as well as those considered  
171 clinically meaningful.

## 172 **Data availability**

173 RNA sequencing raw data and normalized gene counts can be requested to the  
174 corresponding author upon reasonable request.

175

176 **RESULTS**

177 **Baseline characteristics according to degree of fibrosis**

178 Of 130 adults with the Fontan circulation who had 152 liver biopsies (20 patients had 2  
179 liver biopsies and 2 had 3 liver biopsies), 106 patients with 112 adequate RNA quality  
180 samples were included. Fifty-five (51.8%) were women, 71 (66.9%) were white and 29  
181 (27.4%) were Hispanic. Fifteen patients (14.2%) had no fibrosis, 40 (37.7%) had early  
182 fibrosis (F1 in 19 and F2 in 31) and 45 (48.1%) had advanced fibrosis (F3 in 31 and F4  
183 in 14) (Supplemental figure 1). Baseline characteristics are detailed in Table 1. Though  
184 aortopulmonary collaterals were identified all groups, those without fibrosis were more  
185 likely to have aortopulmonary collaterals (46.7% without fibrosis, 10.0% with early  
186 fibrosis, 26.8% with advanced fibrosis,  $p=0.0332$ ). Higher SVR<sub>i</sub> was seen in the group  
187 without fibrosis [25.7 WU·m<sup>2</sup> (9.2) without fibrosis, 19.5 WU·m<sup>2</sup> (11.3) with early  
188 fibrosis, 18.1 WU·m<sup>2</sup> (9.4) with advanced fibrosis,  $p=0.014$ ]. Those with advanced  
189 fibrosis were more likely to be on PDE-5 inhibitors (6.7% without fibrosis, 38.0% with  
190 early fibrosis, 43.9% with advanced fibrosis,  $p=0.033$ ), have diastolic dysfunction  
191 (40.0% without fibrosis, 48.0% with early fibrosis, 70.7% with advanced fibrosis,  
192  $p=0.017$ ) and higher BNP [44 pg/mL (46) without fibrosis, 47 pg/mL (91) with early  
193 fibrosis, 95 pg/mL (130) with advanced fibrosis,  $p=0.016$ ]. Similarly, they also had a  
194 higher VE/VCO<sub>2</sub> slope [(27.1 (6) without fibrosis, 27.7 (5.8) with early fibrosis, 30.9 (6.4)  
195 with advanced fibrosis,  $p=0.009$ ], Fontan [14.0 mmHg (5.0) without fibrosis, 14.5 mmHg  
196 (3.0) with early fibrosis, 17.0 mmHg (6.0) with advanced fibrosis,  $p<0.001$ ], mean  
197 pulmonary artery [13.5 mmHg (5.0) without fibrosis, 14.0 mmHg (3.0) with early  
198 fibrosis, 17.0 mmHg (5.0) with advanced fibrosis,  $p<0.001$ ], and pulmonary capillary

199 wedge [10.0 mmHg (4.0) without fibrosis, 10.0 mmHg (4.0) with early fibrosis, 12.0  
200 mmHg (5.0) with advanced fibrosis,  $p=0.005$ ) pressures.

### 201 **Composite clinical outcome and associated factors**

202 Outcomes among patients with the Fontan circulation according to degree of liver  
203 fibrosis are found in Table 2. Those with advanced liver fibrosis on biopsy were more  
204 likely to experience the composite clinical outcome [0 (0%) without fibrosis, 8 (16.0 %)  
205 with early fibrosis and 15 (36.6%) with advanced fibrosis,  $p=0.005$ ] (Figure 1). None of  
206 the individual components of the composite outcome was significantly associated with  
207 advanced fibrosis. In a multivariable Cox proportional hazards model (Table 3)  
208 controlling for age at Fontan, age at liver biopsy, right ventricular morphology, Fontan  
209 pressure, pulmonary capillary wedge pressure, VE/VCO<sub>2</sub> slope, diastolic dysfunction,  
210 and aortopulmonary collaterals, there was no difference in the risk of the composite  
211 clinical outcome between advanced or early fibrosis. In this multivariable model, there  
212 were differences in the risk of the composite clinical outcome based on age at Fontan  
213 [HR=1.42 (SE 0.18);  $p=0.045$ ], right ventricular morphology [HR=26.01 (SE 1.53);  
214  $p=0.033$ ], and presence of aortopulmonary collaterals [HR=122.77 (SE 1.63);  $p=0.003$ ].

### 215 **FALD has distinct mRNA expression profiles according to degree of fibrosis and** 216 **composite clinical outcome**

217 Liver samples from patients with advanced fibrosis had 231 DEGs (228 up-regulated)  
218 compared to those with early fibrosis (Figure 2A). Liver samples from patients with the  
219 composite clinical outcome had 906 DEGs (894 up-regulated) compared to those  
220 without it (Figure 2B). A total of 136 DEGs were identified in both comparisons and they  
221 were enriched in various cellular responses and signaling pathways, including response

222 to wounding, extracellular matrix organization, regulation of cell adhesion, IL-18, MAPK  
223 and TGF-beta signaling pathways, vasculature development and angiogenesis (Figure  
224 3A). Significant correlations of these 136 DEGs were found with various diseases from  
225 DisGeNET database, including idiopathic pulmonary arterial hypertension, lung  
226 diseases, cardiac fibrosis, vascular diseases, and endothelial dysfunction (Figure 3B).  
227 The distribution of specific DEGs involved in FALD pathophysiology are shown  
228 according to the degree of fibrosis (Figure 4) and presence or absence of the clinical  
229 outcome (Figure 5).

230

## 231 **DISCUSSION**

232 In this first broad analysis of gene expression in liver tissue from a retrospectively  
233 identified cohort of patients with FALD, we reveal several important findings. First,  
234 patients with FALD and advanced fibrosis have a distinct transcriptome versus those  
235 with early fibrosis and controls. Second, patients with FALD and advanced fibrosis are  
236 more likely to experience the composite clinical outcome, but this is mediated by age at  
237 Fontan, right ventricular morphology and presence of aortopulmonary collaterals. Third,  
238 patients with FALD and the composite clinical outcome have a distinct transcriptome  
239 compared to those without the composite clinical outcome. Fourth, we identified  
240 overlapping DEGs between those with advanced fibrosis as well as the composite  
241 clinical outcome, and identified pathways related to pro-inflammatory responses and  
242 increased oxidative stress (HSPB1, IRF1, SOCS3, and NFKB2), impaired vascular  
243 endothelial function (HSPA1A, HSPA1B, ND5, ND6, NR4A2, SOD3, KLF2), enriched  
244 angiogenesis and vasculature development (RHOB, COL1A1, NR4A1, NOTCH3,

245 SERPINE1), TGF-beta signaling pathways, etc. These findings are important given that  
246 an inflammatory infiltrate on liver biopsies was not found, and we excluded samples with  
247 active hepatocellular carcinoma. These results expand our insights into FALD  
248 pathophysiology and show potential candidate genes that could serve as biomarkers of  
249 adverse outcomes.

250  
251 Out of all the overlapping DEGs identified in our study, COL1A1 RASD1, CHI3L1,  
252 MTRNR2, MUC5B, SLCO4A1, SOD3, WNK2 have been previously described in  
253 transcriptomic profiling of obesity-related nonalcoholic steatohepatitis<sup>15</sup>. Our findings  
254 demonstrate that angiogenesis may be particularly important in FALD. This complex,  
255 dynamic and growth factor dependent process leading to the formation of new blood  
256 vessels from preexisting ones, is strongly associated with scar formation and sinusoidal  
257 remodeling in chronic liver diseases<sup>10</sup>. Several genes are involved in this process  
258 including VEGF and ANGPT2<sup>16</sup>. High serum angiopoietin-2 levels (protein expressed  
259 from ANGPT2) have been associated with liver cirrhosis and hepatocellular carcinoma  
260 among samples from nonalcoholic steatohepatitis<sup>17</sup>, and several studies are evaluating  
261 this as a potential therapeutic target<sup>18-20</sup>. In a cohort study involving patients with the  
262 Fontan circulation, angiopoietin-2 levels were found to be significantly higher in patients  
263 with active or recent arrhythmias<sup>21</sup>. Although we did not find ANGPT2 as one of our  
264 overlapping genes, we identified VEGFA-VEGFR2 signaling pathway, which is the  
265 major pathway that activates angiogenesis.

266 Our study had several strengths, including a highly diverse and phenotypically  
267 characterized cohort that had longitudinal care at a large ACHD referral center with

268 expertise in combined heart and liver transplantation, as well as achieving more than  
269 80% high-quality RNA extraction from FFPE liver biopsies. Moreover, the patients had  
270 undergone cardiac catheterization in a standard fashion, limiting the heterogeneity of  
271 hemodynamic measurements. Despite this, several limitations were encountered. First,  
272 intrahepatic gene expression profiles are largely driven by the effect of parenchymal  
273 cells, and this represents a limitation when analyzing bulk transcriptomics. Several  
274 recent discoveries in the molecular biology of liver cirrhosis (from non-cardiac causes)  
275 have highlighted the important role that non-parenchymal liver cells (immune,  
276 endothelial, and mesenchymal cells) play in its development. Gene expression profiles  
277 of non-parenchymal cells are underrepresented in the whole tissue liver RNA-seq data.  
278 Other methods such as single-cell RNA sequencing or digital spatial profiling<sup>22</sup> may be  
279 helpful identifying the gatekeepers of advanced liver fibrosis in FALD. Second, the  
280 assessment of aortopulmonary collaterals was not systematically performed in all  
281 patients unless the patients presented for organ transplantation, and this might  
282 influence our univariate as well as multivariable Cox proportional hazards results. Third,  
283 small cohort size could have influenced the significance of our results.

284 **CONCLUSIONS**

285 Patients with Fontan-associated liver disease exhibit transcriptomic differences  
286 according to the degree of fibrosis and the presence of the clinical composite outcome.  
287 These genes are involved in pathways related to inflammation, congestion, and  
288 angiogenesis.

289

290 **SOURCES OF FUNDING**

291 Dr. Bravo-Jaimes was supported by the Adult Congenital Heart Association Research  
292 Grant 2021. Dr. Klomhaus was supported by the NIH/National Center for Advancing  
293 Translational Science (NCATS) UCLA CTSI Grant Number UL1TR001881. Dr. Bostrom  
294 was supported by NIH/NHLBI Grant Numbers HL81397 and HL154548. Dr. Aboulhosn  
295 was supported by the Streisand/American Heart Association Endowed Chair in  
296 Cardiology. Dr. Kaldas was supported by the Kelly Lee Tarantello Endowed Chair in  
297 Integrative Liver Transplantation.

298

299 **DISCLOSURES**

300 The authors declare no conflicts of interest.

301

302 **TABLES**

303 Table 1. Baseline characteristics of adults with the Fontan circulation according to the  
 304 degree of liver fibrosis.

	<b>No fibrosis n=15</b>	<b>Early fibrosis n=50</b>	<b>Advance d fibrosis n=41</b>	<b>p value</b>
<b>Left systemic ventricle morphology, n (%)</b>	8 (53.3)	35 (70.0)	20 (48.8)	0.078
<b>Age at Fontan (median, IQR)</b>	4.0 (6.0)	5.0 (7.0)	4.0 (5.0)	0.722
<b>Type of Fontan, n (%)</b>				0.363
Atriopulmonary	3 (20.0)	19 (38.0)	12 (29.3)	
Bjork	0 (0.0)	1 (2.0)	1 (2.4)	
Extracardiac	4 (26.7)	5 (10.0)	11 (26.8)	
Lateral tunnel (Intra-atrial included here)	8 (53.3)	23 (46.0)	14 (34.2)	
Other	0 (0.0)	2 (4.0)	3 (7.3)	
<b>Fenestration, n % (patients with available data n=93)</b>	5 (38.5)	12 (27.9)	16 (43.2)	0.350



<b>Fenestration closure, n % (patients with available data n=30)</b>	3 (60.0)	7 (63.6)	12 (85.7)	0.353
<b>Fontan conversion, n %</b>	2 (13.3)	10 (20.0)	15 (36.6)	0.099
<b>Heterotaxy, n %</b>	1 (6.7)	5 (10.0)	7 (17.1)	0.459
<b>Diabetes, n %</b>	0 (0.0)	2 (4.0)	4 (9.8)	0.428
<b>Hypertension, n %</b>	1 (6.7)	3 (6.0)	5 (12.2)	0.712
<b>Hepatitis C, n %</b>	0 (0.0)	2 (4.0)	3 (7.3)	0.693
<b>Obesity, n %</b>	1 (6.7)	8 (16.0)	6 (14.6)	0.752
<b>BMI, median (IQR)</b>	22.7 (5.7)	23.8 (7.6)	24.2 (7.3)	0.957
<b>Hemidiaphragm paresis, n (%)</b>	0 (0.0)	1 (2.0)	2 (4.9)	0.735
<b>Smoking, n (%)</b>	1 (6.7)	3 (6.0)	3 (7.3)	1.000
<b>Alcohol, n (%)</b>	8 (53.3)	18 (36.0)	13 (31.7)	0.327
<b>Drugs, n (%)</b>	4 (26.7)	8 (16.0)	7 (17.1)	0.630
<b>Prior thromboembolism, n (%)</b>	1 (6.7)	14 (28.0)	10 (24.4)	0.218
<b>Protein losing enteropathy, n (%)</b>	0 (0.0)	4 (8.0)	5 (12.2)	0.402

<b>Arrhythmia, n (%)</b>	6 (40.0)	34 (68.0)	25 (61.0)	0.148
<b>Pacemaker, n (%)</b>	4 (26.7)	19 (38.0)	20 (48.8)	0.286
<b>Defibrillator, n (%)</b>	1 (6.7)	1 (2.0)	3 (7.3)	0.352
<b>NYHA class, n (%)</b>				0.064
<b>I</b>	12 (80.0)	26 (52.0)	15 (36.6)	
<b>II</b>	3 (20.0)	17 (34.0)	21 (51.2)	
<b>III</b>	0 (0.0)	5 (10.0)	3 (7.3)	
<b>IV</b>	0 (0.0)	0 (0.0)	2 (4.9)	
<b>Betablockers, n (%)</b>	8 (53.3)	24 (48.0)	18 (43.9)	0.811
<b>PDE-5 inhibitors, n (%)</b>	1 (6.7)	19 (38.0)	18 (43.9)	<b>0.033</b>
<b>ERAs, n (%)</b>	1 (6.7)	2 (4.0)	2 (4.9)	0.841
<b>Antiplatelets, n (%)</b>	9 (60.0)	25 (50.0)	23 (56.1)	0.737
<b>Anticoagulants, n (%)</b>	4 (26.7)	27 (54.0)	19 (46.3)	0.176
<b>Loop diuretics, n (%)</b>	5 (33.3)	28 (56.0)	25 (61.0)	0.178
<b>ACE inhibitors, n (%)</b>	9 (60.0)	23 (46.0)	19 (46.3)	0.610
<b>ARB, n (%)</b>	1 (6.7)	6 (12.0)	2 (4.9)	0.516
<b>Aldosterone antagonists, n (%)</b>	3 (20.0)	17 (34.0)	21 (51.2)	0.068

<b>Digoxin, n (%)</b>	3 (20.0)	9 (18.0)	10 (24.4)	0.754
<b>Other antiarrhythmics, n (%)</b>	2 (13.3)	16 (32.0)	8 (19.5)	0.214
<b>Creatinine (median, IQR)</b>	0.8 (0.2)	0.8 (0.2)	0.9 (0.4)	0.223
<b>Platelets (median, IQR)</b>	170.0 (53.0)	158.0 (82.0)	134.5 (60.0)	0.106
<b>Hemoglobin (median, IQR)</b>	15.5 (4.0)	15.1 (2.9)	15.1 (2.7)	0.692
<b>Albumin (median, IQR)</b>	4.7 (0.6)	4.7 (0.7)	4.4 (1.0)	0.057
<b>INR (median, IQR)</b>	1.2 (0.0)	1.2 (0.3)	1.3 (0.4)	0.230
<b>AFP (median, IQR)</b>	3.0 (8.0)	2.0 (1.0)	3.0 (2.0)	0.489
<b>BNP (median, IQR)</b>	44.0 (46.0)	47.0 (91.0)	95.0 (130.0)	<b>0.016</b>
<b>Systemic ventricle function, n (%)</b>				0.181
Normal or mildly reduced	12 (80.0)	45 (90.0)	31 (75.6)	
Moderately or severely reduced	3 (20.0)	5 (10.0)	10 (24.4)	
<b>AVV regurgitation, n (%)</b>				0.161

None, trace or mild	13 (86.7)	36 (72.0)	25 (61.0)	
Moderate or severe	2 (13.3)	14 (28.0)	16 (39.0)	
<b>Liver US characteristics, n (%) (patients with available data n=88)</b>				
Nodular contour	5 (35.7)	24 (63.2.0)	24 (66.7)	0.118
Splenomegaly	4 (28.6)	11 (29.0)	13 (36.1)	0.772
Abdominal collateral vessels	1 (7.1)	0 (0.0)	1 (2.8)	0.155
Ascites	0 (0.0)	7 (18.4)	8 (22.2)	0.165
Elevated liver stiffness	4 (28.6)	14 (36.8)	14 (38.9)	0.790
Liver mass	0 (0.0)	3 (7.9)	1 (2.8)	0.514
<b>Liver MRI characteristics, n (%) (patients with available data n=25)</b>				
Nodular contour	5 (100.0)	9 (64.3)	4 (66.7)	0.405
Splenomegaly	1 (20.0)	4 (28.6)	3 (50.0)	0.611
Ascites	0 (0.0)	2 (14.3)	2 (33.3)	0.468
Abdominal collateral	0 (0.0)	1 (7.1)	1 (16.7)	0.697

vessels				
Elevated stiffness	0 (0.0)	0 (0.0)	2 (33.3)	0.083
Liver mass	0 (0.0)	0 (0.0)	2 (33.3)	0.083
<b>Liver CT characteristics, n (%) (patients with available data n=54)</b>				
Nodular contour	4 (66.7)	21 (80.8)	20 (90.9)	0.275
Splenomegaly	4 (66.7)	8 (30.8)	15 (68.2)	0.032
Abdominal collateral vessels	2 (33.3)	6 (23.1)	10 (45.5)	0.270
Ascites	3 (50.0)	11 (42.3)	11 (50.0)	0.926
Liver mass	0 (0.0)	3 (11.5)	2 (9.1)	1.000
<b>Baseline O2Sat (median, IQR) (patients with available data n=92)</b>				
<b>Peak O2Sat (median, IQR)</b>	93.0 (3.0)	92.5 (6.0)	92.0 (6.0)	0.655
<b>Exercise-induced desaturation (peak O2 – baseline O2) (median, IQR)</b>	92.0 (5.0)	89.0 (8.0)	90.0 (7.0)	0.616
	2.0 (2.0)	3.0 (5.0)	2.0 (3.0)	0.576

<b>Peak VO2 (median, IQR)</b>	61.0 (17.0)	59.0 (22.0)	55.5 (26.0)	0.645
<b>VE/VCO2 slope (median, IQR)</b>	27.1 (6.0)	27.7 (5.8)	30.9 (6.4)	<b>0.009</b>
<b>High exercise capacity, n (%)</b>	2 (13.3)	6 (12.0)	7 (17.1)	n/a
<b>Low exercise capacity, n (%)</b>	2 (13.3)	9 (18.0)	13 (31.7)	n/a
<b>Fontan pressure, median (IQR)</b>	14.0 (5.0)	14.5 (3.0)	17.0 (6.0)	<b>&lt;.001</b>
<b>Mean PAP, median (IQR)</b>	13.5 (5.0)	14.0 (3.0)	17.0 (5.0)	<b>&lt;.001</b>
<b>Pulmonary capillary wedge pressure, median (IQR)</b>	10.0 (4.0)	10.0 (4.0)	12.0 (5.0)	<b>0.005</b>
<b>Single ventricle end-diastolic pressure, median (IQR)</b>	10.0 (5.0)	10.0 (5.5)	10.0 (3.0)	0.609
<b>Qs, median (IQR)</b>	4.3 (1.4)	4.5 (1.9)	5.0 (2.6)	0.273
<b>Qs index, median (IQR)</b>	2.5 (0.7)	2.7 (1.1)	2.7 (1.6)	0.153
<b>PVR, median (IQR)</b>	0.9 (0.4)	0.9 (0.7)	1.1 (0.8)	0.485

<b>PVRi, median (IQR)</b>	1.7 (0.8)	1.6 (1.3)	2.0 (1.5)	0.674
<b>SVR, median (IQR)</b>	13.0 (4.3)	11.3 (7.3)	10.2 (5.6)	0.067
<b>SVRi, median (IQR)</b>	25.7 (9.2)	19.5 (11.3)	18.1 (9.4)	<b>0.014</b>
<b>Fontan pathway obstruction, n (%)</b>	0 (0.0)	7 (14.0)	8 (19.5)	0.115
<b>Diastolic dysfunction, n (%)</b>	6 (40.0)	24 (48.0)	29 (70.7)	<b>0.017</b>
<b>Elevated PVR, n (%)</b>	4 (26.7)	18 (36.0)	17 (41.5)	0.290
<b>Aortopulmonary collaterals, n (%)</b>	7 (46.7)	5 (10.0)	11 (26.8)	<b>0.006</b>
<b>Venous-venous collaterals, n (%)</b>	8 (53.3)	26 (52.0)	18 (43.9)	0.698

305 \*p-values from chi-square test for independence (or Fisher's exact test when

306 appropriate) for categorical variables, and Kruskal-Wallis test for continuous variables

307 \*\*p-values do not include missing values on any given variable

308 \*\*\* frequencies were calculated among those with available data and not among total N

309 in each column

310

311 Table 2. Outcomes among patients with the Fontan circulation according to liver biopsy  
 312 results.

<b>Outcomes</b>	<b>No fibrosis</b>	<b>Early fibrosis</b>	<b>Advanced fibrosis</b>	<b>P value</b>
<b>Thromboembolism, n (%)</b>	1 (6.7)	1 (2.0)	1 (2.4)	0.527
<b>Arrhythmias, n (%)</b>	4 (26.7)	14 (28.0)	7 (17.0)	0.215
<b>Composite clinical outcome, n (%)</b>	0 (0)	8 (16.0)	15 (36.6)	<b>0.005</b>
<b>Decompensated cirrhosis, n (%)</b>	0 (0)	4 (8.0)	7 (17.1)	0.138
Ascites requiring paracentesis	0 (0)	3 (6.0)	5 (12.2)	0.402
Esophageal variceal bleeding	0 (0)	1 (2.0)	2 (4.9)	0.740
Hepatic encephalopathy	0 (0)	0 (0.0)	0 (0.0)	n/a
<b>Hepatocellular carcinoma, n (%)</b>	0 (0.0)	2 (4.0)	1 (2.4)	1.000
<b>Focal nodular</b>	1 (6.7)	5 (10.0)	5 (12.2)	0.544



<b>hyperplasia, n (%)</b>				
<b>Chronic kidney disease, n (%)</b>	0 (0.0)	1 (2.0)	1 (2.4)	0.115
<b>Fontan circulatory failure, n (%)</b>	1 (6.7)	11 (22.0)	15 (36.6)	0.056
<b>Liver transplant, n (%)</b>	0 (0.0)	5 (10.0)	8 (19.5)	0.109
<b>Heart transplant, n (%)</b>	1 (6.7)	9 (18.0)	13 (31.7)	0.090
<b>Death, n (%)</b>	0 (0.0)	3 (6.0)	3 (7.3)	0.858

313

314 \*Composite clinical outcome of decompensated cirrhosis (ascites requiring  
315 paracentesis, esophageal variceal bleeding, hepatic encephalopathy), hepatocellular  
316 carcinoma, need for liver transplantation, protein-losing enteropathy, chronic kidney  
317 disease stage 4 or higher, or death.

318

319

320 Table 3. Multivariable Cox proportional hazards model for the composite clinical  
321 outcome.

<b>Parameter</b>	<b>Hazard Ratio</b>	<b>Standard Error</b>	<b>P value</b>
<b>Age at Fontan</b>	1.42	0.18	<b>0.045</b>
<b>Right ventricular morphology</b>	26.01	1.53	<b>0.033</b>
<b>Fontan pressure</b>	1.68	0.37	0.162
<b>Pulmonary capillary wedge pressure</b>	1.17	0.24	0.517
<b>VE/VCO2 slope</b>	0.97	0.09	0.744
<b>Diastolic dysfunction</b>	0.08	2.00	0.209
<b>Aortopulmonary collaterals</b>	122.77	1.62	<b>0.003</b>
<b>Age at liver biopsy</b>	0.97	0.10	0.752
<b>Advanced fibrosis</b>	0.19	1.22	0.179

322

323

324


325 **FIGURES**

326 Figure 1. Unadjusted cumulative incidence function comparing time to the clinical  
327 composite outcome, relative to date of Fontan, between patients with early vs advanced  
328 fibrosis.


329

330


331



332 Figure 2. A. Volcano plot showing 231 DEGs (228 up-regulated) in patients with FALD  
333 and advanced fibrosis vs early fibrosis. B. Volcano plot showing 906 DEGs (894 up-  
334 regulated) in patients with FALD and the clinical composite outcomes vs those without  
335 it.




339 Figure 3. A. Gene ontology and pathway enrichment analysis among patients with  
340 advanced liver fibrosis. B. Gene disease association enrichment analysis using 136  
341 DEGs and the DisGeNet platform.




345 Figure 4. Violin plot demonstrating the gene count distribution in specific overlapping

346 genes among patients with FALD according to the degree of liver fibrosis.



347 Figure 5. Violin plot demonstrating the gene count distribution in specific overlapping  
348 genes among patients with FALD according to the presence of the composite outcome.



349

350



351 **REFERENCES**

- 352 1. Fontan F, Baudet E. Surgical repair of tricuspid atresia. *Thorax*. 1971;26:240-  
353 248. doi: 10.1136/thx.26.3.240
- 354 2. Emamaullee J, Zaidi AN, Schiano T, Kahn J, Valentino PL, Hofer RE, Taner T,  
355 Wald JW, Olthoff KM, Bucuvalas J, et al. Fontan-Associated Liver Disease:  
356 Screening, Management, and Transplant Considerations. *Circulation*.  
357 2020;142:591-604. doi: 10.1161/CIRCULATIONAHA.120.045597
- 358 3. Agnoletti G, Ferraro G, Bordese R, Marini D, Gala S, Bergamasco L, Ferroni F,  
359 Calvo PL, Barletti C, Cisarò F, et al. Fontan circulation causes early, severe liver  
360 damage. Should we offer patients a tailored strategy? *Int J Cardiol*. 2016;209:60-  
361 65. doi: 10.1016/j.ijcard.2016.02.041
- 362 4. Goldberg DJ, Surrey LF, Glatz AC, Dodds K, O'Byrne ML, Lin HC, Fogel M,  
363 Rome JJ, Rand EB, Russo P, et al. Hepatic Fibrosis Is Universal Following  
364 Fontan Operation, and Severity is Associated With Time From Surgery: A Liver  
365 Biopsy and Hemodynamic Study. *J Am Heart Assoc*. 2017;6. doi:  
366 10.1161/JAHA.116.004809
- 367 5. Khan S, Aziz H, Emamaullee J. Research priorities in Fontan-associated liver  
368 disease. *Curr Opin Organ Transplant*. 2020;25:489-495. doi:  
369 10.1097/MOT.0000000000000803
- 370 6. Egbe AC, Poterucha JT, Warnes CA, Connolly HM, Baskar S, Ginde S, Clift P,  
371 Kogon B, Book WM, Walker N, et al. Hepatocellular Carcinoma After Fontan  
372 Operation: Multicenter Case Series. *Circulation*. 2018;138:746-748. doi:  
373 10.1161/CIRCULATIONAHA.117.032717

- 374 7. Rychik J, Veldtman G, Rand E, Russo P, Rome JJ, Krok K, Goldberg DJ, Cahill  
375 AM, Wells RG. The precarious state of the liver after a Fontan operation:  
376 summary of a multidisciplinary symposium. *Pediatr Cardiol.* 2012;33:1001-1012.  
377 doi: 10.1007/s00246-012-0315-7
- 378 8. Keung CY, Zentner D, Gibson RN, Phan DH, Grigg LE, Sood S, Nicoll AJ.  
379 Fontan-associated liver disease: pathophysiology, investigations, predictors of  
380 severity and management. *Eur J Gastroenterol Hepatol.* 2019. doi:  
381 10.1097/MEG.0000000000001641
- 382 9. Hilscher MB, Johnson JN, Cetta F, Driscoll DJ, Poterucha JJ, Sanchez W,  
383 Connolly HM, Kamath PS. Surveillance for liver complications after the Fontan  
384 procedure. *Congenit Heart Dis.* 2017;12:124-132. doi: 10.1111/chd.12446
- 385 10. Alsaied T, Rathod RH, Aboulhosn JA, Budts W, Anderson JB, Baumgartner H,  
386 Brown DW, Cordina R, D'Udekem Y, Ginde S, et al. Reaching consensus for  
387 unified medical language in Fontan care. *ESC Heart Fail.* 2021;8:3894-3905. doi:  
388 10.1002/ehf2.13294
- 389 11. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P,  
390 Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner.  
391 *Bioinformatics.* 2013;29:15-21. doi: 10.1093/bioinformatics/bts635
- 392 12. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner  
393 C, Chanda SK. Metascape provides a biologist-oriented resource for the analysis  
394 of systems-level datasets. *Nat Commun.* 2019;10:1523. doi: 10.1038/s41467-  
395 019-09234-6

- 396 13. Pinero J, Bravo A, Queralt-Rosinach N, Gutierrez-Sacristan A, Deu-Pons J,  
397 Centeno E, Garcia-Garcia J, Sanz F, Furlong LI. DisGeNET: a comprehensive  
398 platform integrating information on human disease-associated genes and  
399 variants. *Nucleic Acids Res.* 2017;45:D833-D839. doi: 10.1093/nar/gkw943
- 400 14. Pinero J, Queralt-Rosinach N, Bravo A, Deu-Pons J, Bauer-Mehren A, Baron M,  
401 Sanz F, Furlong LI. DisGeNET: a discovery platform for the dynamical  
402 exploration of human diseases and their genes. *Database (Oxford).*  
403 2015;2015:bav028. doi: 10.1093/database/bav028
- 404 15. Gerhard GS, Legendre C, Still CD, Chu X, Petrick A, DiStefano JK.  
405 Transcriptomic Profiling of Obesity-Related Nonalcoholic Steatohepatitis Reveals  
406 a Core Set of Fibrosis-Specific Genes. *J Endocr Soc.* 2018;2:710-726. doi:  
407 10.1210/js.2018-00122
- 408 16. Bocca C, Novo E, Miglietta A, Parola M. Angiogenesis and Fibrogenesis in  
409 Chronic Liver Diseases. *Cell Mol Gastroenterol Hepatol.* 2015;1:477-488. doi:  
410 10.1016/j.jcmgh.2015.06.011
- 411 17. Lefere S, Devisscher L, Geerts A. Angiogenesis in the progression of non-  
412 alcoholic fatty liver disease. *Acta Gastroenterol Belg.* 2020;83:301-307.
- 413 18. Scholz A, Rehm VA, Rieke S, Derkow K, Schulz P, Neumann K, Koch I, Pascu  
414 M, Wiedenmann B, Berg T, et al. Angiotensin-2 serum levels are elevated in  
415 patients with liver cirrhosis and hepatocellular carcinoma. *Am J Gastroenterol.*  
416 2007;102:2471-2481. doi: 10.1111/j.1572-0241.2007.01377.x
- 417 19. Pauta M, Ribera J, Melgar-Lesmes P, Casals G, Rodriguez-Vita J, Reichenbach  
418 V, Fernandez-Varo G, Morales-Romero B, Bataller R, Michelena J, et al.

- 419 Overexpression of angiotensin-2 in rats and patients with liver fibrosis.  
420 Therapeutic consequences of its inhibition. *Liver Int.* 2015;35:1383-1392. doi:  
421 10.1111/liv.12505
- 422 20. Lefere S, Van de Velde F, Hoorens A, Raevens S, Van Campenhout S,  
423 Vandierendonck A, Neyt S, Vandeghinste B, Vanhove C, Debbaut C, et al.  
424 Angiotensin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target  
425 in Murine Nonalcoholic Fatty Liver Disease. *Hepatology.* 2019;69:1087-1104. doi:  
426 10.1002/hep.30294
- 427 21. Shirali AS, Lluri G, Guihard PJ, Conrad MB, Kim H, Pawlikowska L, Bostrom KI,  
428 Iruela-Arispe ML, Aboulhosn JA. Angiotensin-2 predicts morbidity in adults with  
429 Fontan physiology. *Sci Rep.* 2019;9:18328. doi: 10.1038/s41598-019-54776-w
- 430 22. Lee J, Kim CM, Cha JH, Park JY, Yu YS, Wang HJ, Sung PS, Jung ES, Bae SH.  
431 Multiplexed Digital Spatial Protein Profiling Reveals Distinct Phenotypes of  
432 Mononuclear Phagocytes in Livers with Advanced Fibrosis. *Cells.* 2022;11. doi:  
433 10.3390/cells11213387

434 **SUPPLEMENTAL FIGURES**

435 Supplemental figure 1. Flow diagram of patients and samples included.

436

